Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
February 19, 2025
Lead Product(s) : Meningococcal (Groups A, C, Y and W-135) Conjugate Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovhyaluronidase Azoximer
Therapeutic Area : Urology
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 23, 2024
Lead Product(s) : Bovhyaluronidase Azoximer
Therapeutic Area : Urology
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Influenza Quadrivalent Inactivated Vaccine
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
Details : Undisclosed
Product Name : Grippol Quadrivalent
Product Type : Vaccine
Upfront Cash : Inapplicable
April 26, 2024
Lead Product(s) : Influenza Quadrivalent Inactivated Vaccine
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bovhyaluronidase Azoximer
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 25, 2024
Lead Product(s) : Bovhyaluronidase Azoximer
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Artneo
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Dietary Supplement
Upfront Cash : Inapplicable
September 13, 2023
Lead Product(s) : Artneo
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Collagen Type II
Therapeutic Area : Musculoskeletal
Study Phase : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study of the Feasibility of Using the Dietary Supplement "ARTNEO" in Patients With Osteoathritis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
August 04, 2023
Lead Product(s) : Collagen Type II
Therapeutic Area : Musculoskeletal
Highest Development Status : Undisclosed
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Fosfomycin Trometamol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Study Phase : Undisclosed
Recipient : PharmaLinea
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy and Safety of Uronext® in Women With Cystitis
Details : Undisclosed
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
July 14, 2023
Lead Product(s) : Fosfomycin Trometamol
Therapeutic Area : Obstetrics/Gynecology (Women’s Health)
Highest Development Status : Undisclosed
Recipient : PharmaLinea
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Sponsor : ISU ABXIS
Deal Size : Inapplicable
Deal Type : Inapplicable
Fabagal® for Fabry Disease Management is Now Available in Russia
Details : Fabagal (agalsidase-beta) is a recombinant analogue of human alpha-galactosidase A and is produced by recombinant DNA technology. It is approved for the treatment of fabry disease in adults and children from 8 years old.
Product Name : Fabagal
Product Type : Enzyme
Upfront Cash : Inapplicable
February 10, 2023
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Sponsor : ISU ABXIS
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Study Phase : Approved FDF
Recipient : ISU ABXIS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the agreement, Petrovax gains access to Fabagal (agalsidase beta), indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (α-galactosidase A deficiency).
Product Name : Fabagal
Product Type : Enzyme
Upfront Cash : Undisclosed
January 26, 2022
Lead Product(s) : Agalsidase Beta
Therapeutic Area : Genetic Disease
Highest Development Status : Approved FDF
Recipient : ISU ABXIS
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Chinese COVID-19 Vaccine Ad5-Ncov Shows High Antibody Levels at Russian Trial -Ifax
Details : Russian pharmaceutical company Petrovax on Thursday said 92.5% of Russian volunteers in trials of the Chinese Ad5-Ncov vaccine against COVID-19 had shown high levels of antibodies.
Product Name : Convidecia
Product Type : Vaccine
Upfront Cash : Inapplicable
December 01, 2021
Lead Product(s) : Ad5-nCoV
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : CanSino Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable